An­oth­er Keytru­da com­bo tops stan­dard of care in ad­vanced kid­ney can­cer, pos­ing new test for Bris­tol's I/O med

Locked in a heat­ed bat­tle for I/O su­prema­cy, Mer­ck and Bris­tol have read­i­ly en­gaged in proxy bat­tles for new in­di­ca­tions, tag-team­ing their block­busters with oth­er meds to get a leg up. Now, af­ter al­ready scor­ing a com­bo win with an­oth­er TKI in­hibitor in kid­ney can­cer, Mer­ck is hold­ing up promis­ing da­ta for an­oth­er Keytru­da pair­ing.

A com­bi­na­tion of Keytru­da and Ei­sai’s TKI in­hibitor Lenvi­ma sig­nif­i­cant­ly ex­tend­ed the time pa­tients lived with­out their dis­ease get­ting worse in a head-to-head matchup with TKI drug suni­tinib, the stan­dard of care in first-line ad­vanced re­nal cell cari­no­ma, ac­cord­ing to da­ta pre­sent­ed Sat­ur­day at the vir­tu­al AS­CO GU meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER